CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.govBusiness Wire • 08/19/22
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/22/21
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing FacilityBusiness Wire • 10/22/21
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And InvestorsSeeking Alpha • 07/14/21
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021Business Wire • 06/30/21
CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer PatientsBenzinga • 06/28/21